BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 22858920)

  • 1. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
    Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 10. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T
    Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new oral anticoagulants: a challenge for hospital formularies.
    Merli GJ
    Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Testa L; Agnifili M; Latini RA; Mattioli R; Lanotte S; De Marco F; Oreglia J; Latib A; Pizzocri S; Laudisa ML; Brambilla N; Bedogni F
    QJM; 2012 Oct; 105(10):949-57. PubMed ID: 22771555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dabigatran, a new oral anticoagulant].
    Uchiyama S
    Brain Nerve; 2011 Apr; 63(4):411-5. PubMed ID: 21441645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 17. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Kovács T
    Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.